scholarly journals 255: First trimester serum analytes as predictors of pathologic copy number variants (CNV) on chromosomal microarray analysis (CMA)

2018 ◽  
Vol 218 (1) ◽  
pp. S164
Author(s):  
Moti Gulersen ◽  
Michael Divon ◽  
Stephanie Baum ◽  
David Krantz ◽  
Kristen Maliszewski ◽  
...  
Keyword(s):  
Microarray Analysis ◽  
Copy Number ◽  
Copy Number Variants ◽  
First Trimester ◽  
Chromosomal Microarray ◽  
Chromosomal Microarray Analysis

scholarly journals Clinical Performance of an Ultrahigh Resolution Chromosomal Microarray Optimized for Neurodevelopmental Disorders

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Karen S. Ho ◽  
Hope Twede ◽  
Rena Vanzo ◽  
Erin Harward ◽  
Charles H. Hensel ◽  
...  
Keyword(s):  
Neurodevelopmental Disorders ◽  
Copy Number ◽  
Detection Rate ◽  
Clinical Performance ◽  
Copy Number Variants ◽  
Autism Spectrum ◽  
Chromosomal Microarray ◽  
Chromosomal Microarray Analysis ◽  
Ultrahigh Resolution ◽  
Significant Difference

Copy number variants (CNVs) as detected by chromosomal microarray analysis (CMA) significantly contribute to the etiology of neurodevelopmental disorders, such as developmental delay (DD), intellectual disability (ID), and autism spectrum disorder (ASD). This study summarizes the results of 3.5 years of CMA testing by a CLIA-certified clinical testing laboratory 5487 patients with neurodevelopmental conditions were clinically evaluated for rare copy number variants using a 2.8-million probe custom CMA optimized for the detection of CNVs associated with neurodevelopmental disorders. We report an overall detection rate of 29.4% in our neurodevelopmental cohort, which rises to nearly 33% when cases with DD/ID and/or MCA only are considered. The detection rate for the ASD cohort is also significant, at 25%. Additionally, we find that detection rate and pathogenic yield of CMA vary significantly depending on the primary indications for testing, the age of the individuals tested, and the specialty of the ordering doctor. We also report a significant difference between the detection rate on the ultrahigh resolution optimized array in comparison to the array from which it originated. This increase in detection can significantly contribute to the efficient and effective medical management of neurodevelopmental conditions in the clinic.

scholarly journals Chromosomal Microarray Analysis as First-Tier Genetic Test for Schizophrenia

2021 ◽  
Vol 12 ◽  
Author(s):  
Chia-Hsiang Chen ◽  
Min-Chih Cheng ◽  
Tsung-Ming Hu ◽  
Lieh-Yung Ping
Keyword(s):  
Genetic Testing ◽  
Microarray Analysis ◽  
Copy Number ◽  
Genetic Test ◽  
Molecular Genetic ◽  
Chromosomal Microarray ◽  
Chromosomal Microarray Analysis ◽  
Clinical Settings ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders

Schizophrenia is a chronic, devastating mental disorder with complex genetic components. Given the advancements in the molecular genetic research of schizophrenia in recent years, there is still a lack of genetic tests that can be used in clinical settings. Chromosomal microarray analysis (CMA) has been used as first-tier genetic testing for congenital abnormalities, developmental delay, and autism spectrum disorders. This study attempted to gain some experience in applying chromosomal microarray analysis as a first-tier genetic test for patients with schizophrenia. We consecutively enrolled patients with schizophrenia spectrum disorder from a clinical setting and conducted genome-wide copy number variation (CNV) analysis using a chromosomal microarray platform. We followed the 2020 “Technical Standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen)” to interpret the clinical significance of CNVs detected from patients. We recruited a total of 60 patients (36 females and 24 males) into this study. We detected three pathogenic CNVs and one likely pathogenic CNV in four patients, respectively. The detection rate was 6.7% (4/60, 95% CI: 0.004–0.13), comparable with previous studies in the literature. Also, we detected thirteen CNVs classified as uncertain clinical significance in nine patients. Detecting these CNVs can help establish the molecular genetic diagnosis of schizophrenia patients and provide helpful information for genetic counseling and clinical management. Also, it can increase our understanding of the pathogenesis of schizophrenia. Hence, we suggest CMA is a valuable genetic tool and considered first-tier genetic testing for schizophrenia spectrum disorders in clinical settings.

scholarly journals Performance of Chromosomal Microarray Analysis for Detection of Copy Number Variations in Fetal Echogenic Bowel

2021 ◽  
Vol Volume 14 ◽  
pp. 1431-1438
Author(s):  
Xiangqun Fan ◽  
Hailong Huang ◽  
Xiyao Lin ◽  
Huili Xue ◽  
Meiying Cai ◽  
...  
Keyword(s):  
Microarray Analysis ◽  
Copy Number ◽  
Copy Number Variations ◽  
Chromosomal Microarray ◽  
Chromosomal Microarray Analysis
Sign in / Sign up

Export Citation Format

Share Document